Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC (ChemoSensMM)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2008 by University of Wuerzburg.
Recruitment status was  Recruiting
Sponsor:
Collaborators:
Hiege-Stiftung gegen Hautkrebs
medac GmbH
DCS Innovative Diagnostik Systeme
Information provided by:
University of Wuerzburg
ClinicalTrials.gov Identifier:
NCT00779714
First received: October 22, 2008
Last updated: NA
Last verified: October 2008
History: No changes posted

October 22, 2008
October 22, 2008
October 2008
October 2012   (final data collection date for primary outcome measure)
Disease-specific overall survival [ Time Frame: 4 years ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
Objective response [ Time Frame: 4 years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Prospectively Randomized Phase III Study of an Individualized Sensitivity-Directed Combination Chemotherapy Versus DTIC as First-Line Treatment in Stage IV Metastatic Melanoma

This phase III trial is aimed to investigate the efficacy of an individualized, sensitivity-directed combination chemotherapy in comparison to the standard regimen DTIC.

Two question are aimed to be answered by this study:

  1. Is the individual chemosensitivity index (BICSI) a prognostic / predictive biomarker for chemotherapy ?
  2. Is an individualized, sensitivity-directed combination chemotherapy superior to the standard regimen DTIC in terms of survival and response ?

Melanoma is a cutaneous neoplasm known for its high aggressiveness, its early dissemination of metastases, and its poor prognosis once metastasized. Chemotherapy with dacarbacine (DTIC) is widely accepted as the standard treatment in metastatic melanoma, with reported response rates of about 10%. This poor outcome is assumed to be due to a high chemoresistance intrinsic to melanoma cells. However, other therapeutic options like polychemotherapy, biochemotherapy, immunotherapy as well as targeted agents did not yet prove to be superior to DTIC in multicenter randomized studies.

Therefore, chemotherapy still is considered as the main therapeutic option in advanced metastatic melanoma, and a number of non-standard chemotherapeutics have been tested in small pilot studies to improve treatment efficacy. Even though complete remissions of metastatic lesions could only be observed in a few patients, these observations indicate a subgroup of patients exhibiting high sensitivity to certain anticancer drugs. An in vitro ATP-based chemosensitivity assay has been shown to differentiate between chemosensitive and chemoresistant melanoma patients. A phase-II-study testing this assay in 53 metastatic melanoma patients followed by a sensitivity-directed individualized chemotherapy demonstrated, that the chemosensitivity profile of an individual patient, reflected by the best individual chemosensitivity index (BICSI), correlated with therapy outcome in terms of therapy response and patient overall survival (Ugurel S: Clin Cancer Res 2006). Interestingly, a surprisingly high proportion of about 2/5 of the investigated patient cohort were classified as chemosensitive, the remaining 3/5 were classified as chemoresistant. Objective response was 36.4% in chemosensitive patients compared to 16.1% in chemoresistant patients (p=0.114); progression arrest (CR+PR+SD) was 59.1% versus 22.6% (p=0.01). Chemosensitive patients showed an increased overall survival of 14.6 months compared to 7.4 months in chemoresistant patients (p=0.041).

These encouraging results prompted the initiation of this randomized phase-III-trial investigating an individualized sensitivity-directed combination chemotherapy compared to the current standard treatment DTIC, as first-line treatment in metastatic melanoma. The therapeutics for chemosensitivity testing and treatment of patients were chosen considering the results of the phase-II-trial (paclitaxel+cisplatinum, treosulfan+cytarabine).

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Melanoma
  • Drug: DTIC (dacarbazine)
    1000 mg/m2, d1 every 21 days
    Other Name: detimedac
  • Drug: paclitaxel + cisplatin
    paclitaxel 200 mg/m2 cisplatin 50 mg/m2 d1 every 21 days
    Other Name: taxomedac + cisplatin medac
  • Drug: treosulfan + cytarabine
    treosulfan 2500 mg/m2, d2 cytarabine 100 mg/m2, d1-3 every 21 days
    Other Name: ovastat + alexan
  • Experimental: A (individualized combined chemotherapy)
    Interventions:
    • Drug: paclitaxel + cisplatin
    • Drug: treosulfan + cytarabine
  • Active Comparator: B (DTIC monochemotherapy)
    Intervention: Drug: DTIC (dacarbazine)

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
360
April 2013
October 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically confirmed melanoma of the skin, mucosa, or unknown primary, diagnosed with surgically unresectable distant metastases (stage IV according to AJCC).
  • At least one measurable target lesion according to RECIST, assessed by CT or MRI (tumor assessment by X-ray or ultrasonography only is not allowed).
  • Access to a biopsy of ~1 cm3 from at least one metastatic lesion for in vitro chemosensitivity testing. Cell suspensions from malignant effusions are also eligible.
  • No prior chemotherapy in stage IV (adjuvant chemotherapy in stage III allowed; one prior regimen of immunotherapy or targeted therapy in stage IV allowed).
  • No evidence of brain/CNS metastases. Former history of brain/CNS metastases, which have been treated successfully, and are no longer visible in CT/MRI is allowed.
  • Last complete tumor assessment (CT or MRI of thorax, abdomen and brain) not older than 14 days prior to registration, and not older than 5 weeks prior to onset of study treatment.
  • ECOG/WHO performance index of 0 or 1.
  • Patients must have stopped any kind of previous antineoplastic therapy for at least 2 weeks prior to registration, and at least 4 weeks prior to treatment onset.
  • Patients must not have concurrent or recent malignancies except for surgically cured carcinoma in-situ of the cervix and basal or squamous cell carcinoma of the skin. Patients with previous malignancies, which have been treated with a subsequent disease-free interval of at least 5 years, are eligible.
  • Patient age ≥ 18 years.
  • Adequate hematological, renal and liver function as defined by the following laboratory values performed within 14 days prior to randomisation:

    • absolute neutrophil count (ANC) ≥ 1.5 x 109/l
    • platelet count ≥ 100 x 109/l
    • hemoglobin ≥ 9 g/dl
    • urea and serum creatinine ≤ 2 times upper normal limit (UNL)
    • total and direct serum bilirubin ≤ 2 times UNL
    • GOT or GPT ≤ 2.5 times UNL; ≤ 5 times UNL is allowed in case of liver metastasis
    • alkaline phosphatase < 2.5 times UNL
  • Female patients should not be pregnant or nursing. Women of childbearing potential should be using a highly effective method of birth control (e.g. implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner). For subjects using a hormonal contraceptive method, information regarding the product under evaluation and its potential effect on the contraceptive should be addressed.
  • Male patients should use an effective method of contraception.
  • Before registration, written informed consent must be given according to GCP guidelines and national/local regulations. Patients must be willing and giving informed consent to participation in the trial.

Exclusion Criteria:

  • All metastatic lesions are surgically resectable.
  • Prior chemotherapy in stage IV (adjuvant chemotherapy in stage III allowed; one prior regimen of immunotherapy or targeted therapy in stage IV allowed).
  • Primary melanoma of the uvea / choroidea.
  • Evidence of brain/CNS metastases. Former history of brain/CNS metastases, which have been treated successfully, and are no longer visible in CT/MRI is allowed.
  • ECOG/WHO performance index of 2 or higher
  • Concurrent or recent malignancies except for surgically cured carcinoma in-situ of the cervix and basal or squamous cell carcinoma of the skin. Patients with previous malignancies, which have been treated with a subsequent disease-free interval of at least 5 years, are eligible.
  • Any severe or uncontrolled hematological, renal or liver dysfunction as defined by the laboratory values given in Inclusion Criteria.
  • Any clinically uncontrolled infectious disease including HIV positivity or AIDS-related illness.
  • Any female patients who are pregnant or nursing.
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration for the trial.
Both
18 Years and older
No
Contact: Selma Ugurel, Prof. (MD) 0049931201 ext 26118 Ugurel_S@klinik.uni-wuerzburg.de
Germany
 
NCT00779714
101.321-13/07, EudraCT Nr. 2008-001686-28
Yes
Prof. Dr. med. Selma Ugurel, Dept of Dermatology, University of Wuerzburg
University of Wuerzburg
  • Hiege-Stiftung gegen Hautkrebs
  • medac GmbH
  • DCS Innovative Diagnostik Systeme
Study Chair: Selma Ugurel, Prof. (MD) Dept of Dermatology, University of Wuerzburg
University of Wuerzburg
October 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP